Telix Announces Licence Agreement with Lilly for Olaratumab
Telix announces a licence agreement for Lilly’s olaratumab antibody, for diagnosis and treatment of human cancers.
PSMA-PET Imaging to be Funded through Medicare in Australia from July
Telix welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for patients with prostate cancer on the Medicare Benefits Schedule (MBS) from 1 July 2022.
Telix, GMS and Monash Awarded $23M Federal Government Funding as part of $71M Australian Precision Medicine Enterprise (APME) Project
Telix announces that it is part of a $71.2 million Australian Precision Medicine Enterprise Project, which has been awarded $23 million in Federal Government funding
Commercial Launch: Illuccix® Now Available to Order in the United States
Telix announces that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), also known as 68Ga-PSMA-11 injection, is now commercially available in the United States.
Change of Composition of the Telix Board of Directors
Telix announces that Tiffany Olson has been appointed to the Board, as a U.S.-based independent Non-Executive Director.
Telix and Xiel Sign U.K. and Ireland Distribution Agreement for Illuccix®
Telix announces agreement with Xiel for the distribution of Telix’s prostate cancer investigational imaging product, Illuccix® in the UK and Republic of Ireland
ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
Telix announces the ZIRCON Phase III study of investigational kidney cancer imaging agent, TLX250-CDx has dosed the target enrolment of 252 patients.
Telix Releases Results for the Year Ended 31 December 2021 and 2021 Annual Report
Telix Pharmaceuticals Limited Releases Full-Year 2021 Results and 2021 Annual Report.
Telix Enters Commercial Distribution Agreement for Illuccix® in Australia
Telix announces a commercial distribution agreement with Global Medical Solutions Australia (GMSA), for Illuccix® in the Australian market
Telix and SHINE partner for Lutetium-177 Supply
Telix announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for lutetium-177